Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

NCT04948333 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: ABL001 40mg BID
DRUG: ABL001 80mg QD
DRUG: ABL001 200mg QD

Sponsor

Novartis Pharmaceuticals